West Pharmaceutical Services (WST) Q3 2026 earnings review
West's high-value drug stoppers accelerate, while contract manufacturing shrinks
West Pharmaceutical Services, a maker of rubber stoppers and injectors for injectable drugs, grew faster and earned wider profit margins as its highest-priced components rebounded. Sales from businesses owned a year ago rose 12%, and profit per share excluding one-offs climbed 36% while factory costs fell as a share of revenue. New chief executive Michel Lagarde raised the full-year outlook, but by our math the plan points to underlying sales growth slowing to about 6% in the fourth quarter.
| Sales from businesses owned a year ago | +11.9% above the 7.0–8.9% plan |
|---|---|
| High-Value Product Components underlying sales | +20.3% 53% of total company sales |
| Profit per share, excluding one-offs | $2.66 +35.7% from a year ago |
| Full-year sales outlook | Raised $52.5M middle of the range: $3.415B |
⚖️ Verdict: 🟢 Bullish
The story got better because the flagship High-Value Product Components division sped back up to 20% underlying growth after slowing in the spring, while the company cut its full-year factory spending plan by $45 million and bought back $231 million of stock. One caution: almost the entire full-year outlook raise came from the third-quarter beat, and the West Vantage contract-manufacturing division shrank 7% as a major glucose-monitor contract ended.
The question now is whether the component rebound and 40% gross margin rest on rising unit volumes or on temporary price surcharges. If volume carried the quarter, the implied fourth-quarter slowdown is simply cautious budgeting; if price carried it, growth will cool as surcharges lap. The price-versus-volume table in the quarterly filing and fourth-quarter component sales will settle it.
🐂 Bull Case
High-Value Components Rebound Lifted Profit Margins
"Our results were again led by our High-Value Product (HVP) Components business," chief executive Michel Lagarde said in his first quarterly release since taking the role in August. HVP Components are specialised stoppers and plungers for injectable medicines, and they carry the highest profit margins at West Pharmaceutical Services. After slowing in the second quarter, underlying sales growth in this line sped back up, lifting the division to 53% of total sales.
- HVP Components underlying sales: $469.1 million, up 20.3% from a year ago
- Cost of making products: 60.3% of sales, down 3.1 percentage points from a year ago by our math
- Gross margin: 39.7%, up 3.1 percentage points from a year ago
- Operating margin excluding one-offs: 25.3%, up 4.2 percentage points from a year ago
The company also completed the sale of its SmartDose 3.5mL wearable injector business to drugmaker AbbVie, bringing in $118 million of net cash and a $55.7 million pre-tax gain. Removing that lower-margin product and selling more high-value stoppers pushed the Proprietary Products segment gross margin up 3.6 percentage points to 44.4% by our math.
What to watch: the price-versus-volume breakdown in the third-quarter filing. A large volume figure would show that customer demand, rather than temporary price surcharges, drove the 20.3% components gain.
Asia Pacific and Delivery Devices Accelerate
Growth broadened beyond North America and Europe as Asia Pacific sales from businesses owned a year ago rose 41.9% to $96.8 million, speeding up from 27.0% growth in the second quarter. At the same time, HVP Delivery Devices—auto-injectors and pens sold without the divested SmartDose line—grew 26.4% on an underlying basis to $87.6 million.
Earlier quarters had raised questions about whether delivery-device growth relied on final orders for the divested SmartDose product before its July handover. Stripping SmartDose out of both periods proves the remaining device lines are growing over 25% on their own. What to watch: fourth-quarter underlying device growth now that West expects no further SmartDose sales.
Buybacks and Lower Factory Spending Boost Per-Share Profit
The company cut its full-year factory spending plan to $215–220 million from $250–275 million, after spending just $39.1 million in the third quarter by our math. Because existing plants are producing more components without new buildings, West is sending more cash to shareholders: it bought back $231 million of stock in the quarter ($685.3 million year to date) and raised its quarterly dividend 18% to $0.26 per share.
Those buybacks reduced the diluted share count by 2.5% from a year ago to 70.8 million, turning a 32.5% rise in net profit excluding one-offs into 35.7% per-share growth. What to watch: whether management authorises another buyback programme once the remaining $315 million on its current $1 billion plan runs out.
Positives this quarter didn't test
Two standing growth drivers depend on details that only appear on the earnings call or in the quarterly filing, neither of which is in the release.
- European Annex 1 quality-upgrade projects: last quoted at nearly 800 projects contributing about 2 percentage points to annual sales growth; the call will show whether the project count rose and whether the basis stayed consistent.
- Factory productivity programme: expanded across all five high-value component plants last quarter; the lower capital-spending outlook supports it, but throughput figures await the call.
🐻 Bear Case
West Vantage Sales Dropped as Contract Ended
West Vantage, the contract-manufacturing division that builds medical devices and handles drugs for pharmaceutical clients, saw sales fall 7.3% to $145.7 million, or 6.6% on an underlying basis. A large continuous-glucose-monitor contract exited in the third quarter, creating a planned $40 million revenue gap in the second half of the year while a new drug-handling facility in Dublin ramps up.
Segment gross margin recovered from a cyber-disrupted 14.2% in the second quarter to 16.5% by our math, confirming that the new Dublin work carries better economics than the lost contract. Even so, segment gross margin remained 2.8 percentage points below last year's 19.3%, and operating profit fell 30.5% to $15.5 million. What to watch: fourth-quarter West Vantage sales, which must rise above $145.7 million to confirm the third quarter was the bottom.
The Raised Plan Still Points to a Slow Fourth Quarter
"As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance," chief executive Michel Lagarde said. The company raised the middle of its full-year sales plan by $52.5 million and its per-share profit plan excluding one-offs by $0.48. However, third-quarter sales beat the middle of West's own third-quarter plan by $47.0 million, and per-share profit beat by $0.47.
That means almost the entire full-year raise came from the quarter already finished. By our math, the updated full-year plan leaves fourth-quarter reported sales at $823.3 million (up 2.3% from a year ago), underlying sales growth at about 6.3%—half the third-quarter pace—and profit per share excluding one-offs at $2.27, down 39 cents from the third quarter.
What to watch: fourth-quarter underlying sales growth against that implied 6.3% mark. Another five-percent beat would show the new chief executive kept the cautious forecasting habit of his predecessor rather than flagging a real year-end slowdown.
Risks this quarter didn't answer
Five standing concerns could not be fully tested from the earnings release alone, though legal and cyber costs remained on the income statement.
- GLP-1 weight-loss and diabetes drug exposure: last disclosed at 18% of revenue alongside questions over oral pill competition and multi-dose pens; awaits call commentary.
- Price increases versus volume: whether price stayed near 4 percentage points of growth or eased back toward the 2–3% normal band awaits the quarterly filing's sales bridge.
- Long-range targets: whether Lagarde keeps the undated 7–9% underlying growth and 23% operating-margin goals was not addressed in the release.
- Cybersecurity and legal fees: West recorded another $1.8 million of one-off professional fees for "certain legal matters and our cybersecurity incident from May 2026" ($9.2 million year to date); the filing will update the pending shareholder lawsuit.
- Daikyo supplier contract: economics of the ten-year renewal with 49%-owned Japanese partner Daikyo signed in July remain undisclosed.
👓 Other Themes
Currency Flipped From a Tailwind to a Slight Drag
Foreign currency translation reduced reported third-quarter sales by $4.0 million, or 0.5 percentage points of growth, led by a $5.6 million drag in Europe, the Middle East and Africa. In the first half of 2026, a weaker US dollar had added $48.5 million to reported revenue, so the currency tailwind has ended even though the impact was slightly smaller than the 1.1-point drag management had budgeted.
💲 Other KPIs
Uncollected customer bills rose 19.7% from a year ago and 30.3% from year-end, more than double the 8.7% pace of reported sales. That $208.2 million working-capital build pushed nine-month operating cash flow down 19.9% to $403.4 million, even though nine-month net income jumped 40.2%.
Inside Proprietary Products, underlying sales to Pharma customers sped up to 21.4% growth ($221.3 million reported) from 1.6% in the second quarter. Biologics customers grew 23.2% on an underlying basis ($379.3 million reported) after stripping out the divested SmartDose product, keeping the two largest customer groups above 20% growth.
Sales to generic-drug makers fell 5.7% as reported and 4.5% on an underlying basis, reversing after 9.8% underlying growth in the first quarter and 6.7% in the second quarter. Generics accounted for 18% of Proprietary Products revenue in the quarter.
🔮 Guidance
Raised. The middle of the range moved up $52.5 million to $3.415 billion, or 11.1% reported growth. By our math, that leaves $823.3 million for the fourth quarter—up just 2.3% from a year ago because the divested SmartDose product contributed $25.5 million last fourth quarter and "No additional SmartDose® 3.5mL product sales are expected for the remainder of the year". Third raise this year: +$77.5M, +$40.0M, +$52.5M.
Raised. The plan lifts full-year underlying growth by nearly one percentage point at the middle of the range to 11.45%. Because underlying sales already grew 13.2% across the first nine months, the full-year outlook implies fourth-quarter underlying growth slows to about 6.3% by our math, down from 11.9% in the third quarter.
Raised. The middle of the range rose $0.48 to $9.43, or 29.4% growth over 2025. With $7.16 already earned in the first nine months, the outlook leaves $2.27 for the fourth quarter by our math—up 11.3% from a year ago, but down 14.7% from the third quarter. Third raise this year: +$0.55, +$0.375, +$0.48.
Raised. The middle of the unadjusted per-share profit range rose $0.225 to $9.36, or 37.8% growth over 2025's $6.79. The range includes a $0.36 full-year net gain from M&A and the SmartDose sale, offset by $0.26 of restructuring charges and $0.10 of legal and cyber fees.
Cut. The company reduced planned factory spending by $45 million at the middle of the range, to $217.5 million (down 23.9% from 2025). Having spent $125.0 million in the first nine months, the plan still implies $92.5 million of spending in the fourth quarter by our math, more than double the third quarter's $39.1 million pace.
❓ Key Questions
How much of the 20% component growth came from price?
High-Value Product Components sped up to 20.3% underlying growth, and gross margin jumped 3.1 percentage points. Last quarter, price increases supplied 4 percentage points of growth—above the normal 2–3% band—so investors need the third-quarter price-versus-volume split from the filing.
Why has accounts receivable grown twice as fast as sales?
Accounts receivable reached $748.2 million, up 19.7% from a year ago and $173.8 million since December, draining $208.2 million from nine-month operating cash flow. Management has not explained whether extended customer payment terms or shipment timing caused the build.
What is the Annex 1 project count on a consistent basis?
The press release gave no update on European regulatory upgrade projects, which management has quoted on shifting definitions across the past six quarters. A consistent count of initiated versus revenue-generating projects is needed to judge 2027 growth.
Will the new chief executive keep the 23% margin target?
Operating margin excluding one-offs reached 25.3% this quarter and 23.1% across the first nine months, already above the undated 23% long-range target that was deferred to Michel Lagarde before he took office on August 31.